Novartis Acquires IFM Due for $835 Million

Novartis, a leading pharmaceutical company, recently announced its acquisition of IFM Due, a subsidiary of IFM Therapeutics, in a deal worth $835 million. This acquisition follows Novartis' previous purchase of another sister company and marks the culmination of a four-year preclinical collaboration between the two entities.

Under the terms of the agreement, Novartis will gain full rights to IFM Due's portfolio of STING antagonists, a promising collection of products with significant potential in treating inflammation-driven diseases characterized by excessive interferon and other pro-inflammatory cytokine signaling. Richard Siegel, Global Head of Immunology Research at Novartis, expressed enthusiasm for the acquisition, stating that it represents a milestone in their collaboration with IFM and their joint efforts to develop novel small-molecule STING inhibitors for a range of inflammatory conditions.

The cGAS-STING signaling pathway plays a crucial role in perceiving abnormal DNA accumulation in the cytoplasm of cells. Activation of this pathway induces the expression of various pro-inflammatory cytokines, including type I interferons, ultimately triggering an immune response. Targeting this pathway holds significant clinical value in combating infectious diseases and tumors. Recognizing this potential, Novartis entered into a partnership with IFM in 2019 to jointly develop immune therapies inhibiting the cGAS-STING pathway for the treatment of a wide range of inflammatory and autoimmune diseases.

The IFM Due acquisition, valued at $835 million, is not Novartis' first transaction with IFM. In September 2019, they signed a collaboration agreement to develop cGAS-STING pathway inhibitors, with Novartis committing to fully fund IFM Due's research and development costs. As part of this agreement, Novartis secured an option to acquire IFM Due for a total consideration of up to $840 million. Novartis has also completed other deals with IFM's subsidiary companies, including the acquisition of IFM Tre, which granted Novartis full rights to the NLRP3 inhibitors developed by IFM Tre.

In addition to its collaboration with IFM, Novartis has engaged in partnerships and acquisitions with other biotech companies. In February 2024, Novartis announced its acquisition of German biotechnology company MorphoSys for a total cash consideration of €2.7 billion ($2.9 billion). This deal expands Novartis' oncology product line by granting them rights to MorphoSys' drugs, "pelabresib" and "tulmimetostat." Pelabresib, a potential BET inhibitor, aims to suppress abnormal gene expression in cancer by inhibiting the function of BET proteins.

Furthermore, Novartis has formed a strategic collaboration and licensing agreement with Voyager Therapeutics to develop gene therapies for Huntington's disease and spinal muscular atrophy. This partnership involves an upfront payment of $100 million, including the purchase of $20 million worth of Voyager's equity. Novartis has committed to paying milestone fees of up to $1.2 billion for preclinical, development, regulatory, and commercialization activities, as well as tiered royalties on global net sales of any products resulting from the collaboration.

Novartis' continued pursuit of partnerships and acquisitions, including its ongoing collaboration with IFM, exemplifies its commitment to innovation and expanding its portfolio of transformative medicines. The pharmaceutical giant remains at the forefront of scientific advancements and strives to address unmet patient needs in various therapeutic areas.

In conclusion, Novartis' acquisition of IFM Due underscores its dedication to advancing immunology research and developing groundbreaking therapies for inflammatory diseases. This strategic move further solidifies Novartis' position as a leader in the pharmaceutical industry.